The drug dexamethasone supplements cancer treatments to alleviate side effects of chemotherapy such as nausea or inflammation. Researchers at the University of Basel, Switzerland, have now discovered ...
Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT®, a three-fold reduction from 67.4 percent historically seen with standard IRR management In ...
Immune-related adverse events associated with nivolumab: Analysis of the FAERS database in the United States. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does ...
The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for select patients newly diagnosed with multiple myeloma. The Food and Drug Administration (FDA) has approved Darzalex Faspro ...
Johnson & Johnson reports Phase 3 results showing Tecvayli reduced disease progression and deaths in multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results